Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings

Benzinga

02/09

Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings.

The company posted quarterly adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer’s drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis.

“Our 2025 performance reflected continued focus on strong execution and financial discipline, driven by our revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, progression of our pipeline, and resilience of our MS franchise,” commented Christopher Viehbacher, President and CEO.

Biogen expects fiscal 2026 earnings between $15.25 and $16.25 per share, versus the consensus of $14.92. The company expects revenue to decline by mid-single digits compared to 2025, as further declines in Multiple sclerosis product revenue, excluding Vumerity, are expected to be partially offset by increases in revenue from growth

Biogen shares fell 0.9% to $199.40 in pre-market trading.

These analysts made changes to their price targets on Biogen following earnings announcement.

Piper Sandler analyst David Amsellem maintained Biogen with a Neutral and raised the price target from $157 to $177.
HC Wainwright & Co. analyst Andrew S. Fein maintained the stock with a Buy and raised the price target from $194 to $228.
Wedbush analyst Laura Chico maintained Biogen with a Neutral and boosted the price target from $178 to $187.

Considering buying BIIB stock? Here’s what analysts think:

Photo via Shutterstock

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2610558636"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610558636\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610558636?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610558636","market":"us","top_or_hot":-1,"title":"Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings","media":"Benzinga","content":"<html><body><p><strong>Biogen Inc.</strong> (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings.</p>\n<p>The company posted quarterly adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer’s drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis.</p>\n<p>“Our 2025 performance reflected continued focus on strong execution and financial discipline, driven by our revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, progression of our pipeline, and resilience of our MS franchise,” commented Christopher Viehbacher, President and CEO.</p>\n<p>Biogen expects fiscal 2026 earnings between $15.25 and $16.25 per share, versus the consensus of $14.92. The company expects revenue to decline by mid-single digits compared to 2025, as further declines in Multiple sclerosis product revenue, excluding Vumerity, are expected to be partially offset by increases in revenue from growth</p>\n<p>Biogen shares fell 0.9% to $199.40 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Biogen following earnings announcement.</p>\n<ul>\n<li>Piper Sandler analyst David Amsellem maintained Biogen with a Neutral and raised the price target from $157 to $177.</li>\n<li>HC Wainwright &amp; Co. analyst Andrew S. Fein maintained the stock with a Buy and raised the price target from $194 to $228.</li>\n<li>Wedbush analyst Laura Chico maintained Biogen with a Neutral and boosted the price target from $178 to $187.</li>\n</ul>\n<p><strong>Considering buying BIIB stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"511\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171-1024x511.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171-1024x511.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171-768x383.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171.png 1197w\" width=\"1024\"/></figure>\n<p>Photo via Shutterstock</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2026-02-09 21:36</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong>Biogen Inc.</strong> (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings.</p>\n<p>The company posted quarterly adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer’s drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis.</p>\n<p>“Our 2025 performance reflected continued focus on strong execution and financial discipline, driven by our revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, progression of our pipeline, and resilience of our MS franchise,” commented Christopher Viehbacher, President and CEO.</p>\n<p>Biogen expects fiscal 2026 earnings between $15.25 and $16.25 per share, versus the consensus of $14.92. The company expects revenue to decline by mid-single digits compared to 2025, as further declines in Multiple sclerosis product revenue, excluding Vumerity, are expected to be partially offset by increases in revenue from growth</p>\n<p>Biogen shares fell 0.9% to $199.40 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Biogen following earnings announcement.</p>\n<ul>\n<li>Piper Sandler analyst David Amsellem maintained Biogen with a Neutral and raised the price target from $157 to $177.</li>\n<li>HC Wainwright &amp; Co. analyst Andrew S. Fein maintained the stock with a Buy and raised the price target from $194 to $228.</li>\n<li>Wedbush analyst Laura Chico maintained Biogen with a Neutral and boosted the price target from $178 to $187.</li>\n</ul>\n<p><strong>Considering buying BIIB stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"511\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171-1024x511.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171-1024x511.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171-768x383.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/09083458/image-171.png 1197w\" width=\"1024\"/></figure>\n<p>Photo via Shutterstock</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/02/50477635/biogen-analysts-boost-their-forecasts-after-upbeat-q4-earnings","article_id":"2610558636","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610558636","pubTimestamp":1770644161,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司"},"translate_title":"百健(Biogen)分析师在第四季度盈利乐观后上调预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1.5},"content_text":"Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings.\nThe company posted quarterly adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer’s drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis.\n「Our 2025 performance reflected continued focus on strong execution and financial discipline, driven by our revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, progression of our pipeline, and resilience of our MS franchise,」 commented Christopher Viehbacher, President and CEO.\nBiogen expects fiscal 2026 earnings between $15.25 and $16.25 per share, versus the consensus of $14.92. The company expects revenue to decline by mid-single digits compared to 2025, as further declines in Multiple sclerosis product revenue, excluding Vumerity, are expected to be partially offset by increases in revenue from growth\nBiogen shares fell 0.9% to $199.40 in pre-market trading.\nThese analysts made changes to their price targets on Biogen following earnings announcement.\n\nPiper Sandler analyst David Amsellem maintained Biogen with a Neutral and raised the price target from $157 to $177.\nHC Wainwright & Co. analyst Andrew S. Fein maintained the stock with a Buy and raised the price target from $194 to $228.\nWedbush analyst Laura Chico maintained Biogen with a Neutral and boosted the price target from $178 to $187.\n\nConsidering buying BIIB stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}